SearchPublisher and Institutes
You are here: Home :: Area NEM :: Medical science :: Human medicine
Joshua A. Beckman, Kelly Dunn, Arthur A. Sasahara, Samuel Z. Goldhaber
Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism
Conventional anticoagulation for symptomatic pulmonary embolism consists of continuous intravenous unfractionated heparin as a bridge to oral anticoagulation. This strategy requires 5 days or more of intravenous heparin while oral vitamin K antagonists gradually achieve a therapeutic effect. Oral vitamin K antagonists require frequent blood testing to optimize dosing, and their interactions with other medications and foods make regulation difficult. Therefore we tested a different approach to therapy: long-term enoxaparin monotherapy. We randomized 60 symptomatic pulmonary embolism patients in a 2:1 ratio to 90 days of enoxaparin as monotherapy without warfarin (N=40) or to intravenous unfractionated heparin as a bridge to warfarin, target INR 2.03.0 (N=20). Enoxaparin patients received 1 mg/kg twice daily for 14 days during the acute phase followed by randomized assignment during the chronic phase to 1.0 mg/kg vs. 1.5 mg/kg once daily. In an intention-to-treat analysis, 3 of the 40 enoxaparin patients developed recurrent venous thromboembolism compared with 0 of 20 standard therapy patients (p = 0.54). One of the 40 enoxaparin patients had a major hemorrhagic complication compared with 2 of the 20 standard therapy patients (p = 0.26). Median hospital length of stay was shorter with enoxaparin compared to standard therapy (4 vs. 6 days) (p = 0.001). Following our study we can conclude that extended 3-month treatment with enoxaparin as monotherapy for symptomatic, acute pulmonary embolism is feasible and warrants further study in a large clinical trial.
Thrombosis and Haemostasis, Schattauer
Print ISSN: 0340-6245
Volume: 89, 06/2003
Pages: 953 - 958